EYPT · EyePoint, Inc.

Track EYPT — free

$3.16 +0.01 (+0.32%)

Russell 2000 member Rebalance outlook locked

Market Cap

$312.09M

86.21M

Volume · Oct 5 2.76M Avg daily vol (3M) 3.88M

Up next

Next earnings call

Nov 22, 2026 Est · unconfirmed · in 7 wks

Latest filing: 10-Q

filed Aug 5, 2026

Q1 2026 earnings call transcript

call held May 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$2.79M

Trailing 12 months

Net income (TTM)

−$306.64M

Trailing 12 months

Revenue growth YoY

-90.5%

Year over year

Operating margin

-11,369.3%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-86.9%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+23.8%

Year over year · more shares

Price change (1Y)

-75.9%

Trailing year

Short interest

23.0%

Latest settlement · 6.4 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Fair Quant / Vol Very High

Market backdrop VIX 15.5 · calm Equity put/call 0.59

Technical

price trend

Sell

50 / 200-day cross No cross

Price vs 200-day avg −75%

below

Price vs 50-day avg −54%

below

RSI (14) 29

oversold

MACD trend Positive

52-week position 0%

near low

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Weak

1-month return −31%

trailing

6-month return −78%

trailing

YTD return −83%

this year

Relative strength −90%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $7 › 200d $12 — 200d above 50d

Institutional flow Distributing

2 of 194 funds reported for Sep 30 · net -573 sh shares

Insider flow Accumulating

Net +$52.3K over 90 days · 0% sells

Short interest Rising

22.98% of float · ▲ +9.4% MoM · 6.4 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

194 holders — near 3-yr high, broad support

Squeeze score 71

high risk · 0–100

Fundamentals

Fair

Revenue growth +365%

Y/Y

EPS growth −37%

Y/Y

Free cash flow $-243.4M

Balance sheet $65.6M

net cash

Quant / Vol

risk profile

Very High

Volatility 99%

annualized · 1-yr

Max drawdown −83%

past year

ATR 12.9%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell

3 · 3 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−75% Bearish

Price vs 50-day avg

−54% Bearish

RSI (14)

29 Neutral

MACD trend

Positive Bullish

52-week position

0% Bearish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $7 › 200d $12 — 200d above 50d

Institutional flow Distributing

2 of 194 funds reported for Sep 30 · net -573 sh shares

Insider flow Accumulating

Net +$52.3K over 90 days · 0% sells

Short interest Rising

22.98% of float · ▲ +9.4% MoM · 6.4 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

194 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $3 Now $3 · 0% Range high $19

vs 200-day avg -75% vs 50-day avg -54%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
cash and investments supports operational runway	$180M	as of June 30, 2026	—
Patients enrolled in COMO and CAPRI Phase 3 DME trials	480	Q2 2026	—
Patients enrolled in LUGANO and LUCIA Phase 3 wet AMD trials	900	Q2 2026	—
Patients previously treated with DURAVYU across four clinical trials	190	Q2 2026	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
EYPT EyePoint, Inc. this stock	$312.09M	-82.8%	+664.9%	—	23.0%
VRTX Vertex Pharmaceuticals Inc / Ma	$133.37B	+11.1%	+46.2%	30.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$81.13B	-5.9%	+20.8%	19.5	2.5%
MRNA Moderna, Inc.	$79.40B	+589.1%	+4.3%	—	8.2%
CSLLY Csl Ltd	$61.25B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

194

% held: 112.8%
Reported: 2 of 194
Top holder: SUVRETTA CAPITAL MANAGEME…

Held Float

View

Held by Funds

Fund positions

173

View

Short & Settlement

Short Interest Rising

Shares short

19.8M

Days to cover: 6.4d
Change: +1.7M sh

View

Short Volume

Short vol %

60%

As of: Oct 5, 2026

Short Total

View

Fails to Deliver

FTD shares

Value: $215
As of: Sep 2, 2026

View

Off-Exchange

Off-exchange %

47.4%

Week of: Aug 31, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net buying

Net (90d)

+$52.3K

Buyers / Sellers: 1 / 0

Buyers Sellers

View

Financials

Revenue (FY)

$31.4M

Net income (FY): $-232.0M
EPS diluted: $-3.17

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Sep 15, 2026
This year: 21

View

Proposed Sales

Value

$5.5M

Shares: 421.2K
Filed: Jul 21, 2026

View

Exempt Offerings

Offering

$15.7M

Filed: Jan 6, 2021

View

Earnings & Events

Webcasts

Last webcast

Sep 15, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
EYPT	-4.8%	-31.2%	-78.0%	-3.7%	-82.8%
SPY	+1.2%	+0.6%	+11.6%	+1.6%	+13.6%
vs SPY	-6.0%	-31.8%	-89.6%	-5.3%	-96.4%

Key facts CIK 1314102 CUSIP 30233G209 13F (30d) 4 filings 4 filers Visit website Investor relations

EYPT · EyePoint, Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance